

Supplemental Tables for:
 Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer
 Mario Lacouture et al.

Table S1. NSCLC patients treated with osimertinib referred for dAE at MSKCC

Age (y)	Sex	AE (grade)	Intervention	AE outcome	Additional information (histology, lab values)
60	F	Xerosis (2) Skin infection (1) Brittle nails (1)	Ammonium lactate 12% Mupirocin 2% ointment Biotin 2.5 mg/d Poly-ureaurethane 16% nail solution	PR	Culture: MRSA
72	F	Pruritus (2)	Doxepin HCl 5% cream, diclofenac sodium gel	PR	Specimen submitted and diagnosis: 1. Skin histology analysis, left upper back scapular region, biopsy-punch 2. Dermal melanophages and focal perifollicular granulomatous dermatitis; the findings may be due to a resolving interface dermatitis and/or folliculitis; deeper levels were examined.
68	F	Thin nails (1) Xerosis (2)	Biotin 2.5 mg/d Triamcinolone acetonide ointment	PR	
55	F	Xerosis (1)	OTC moisturizer	PR	

Supplemental Tables for:
Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer
Mario Lacouture et al.

Age (y)	Sex	AE (grade)	Intervention	AE outcome	Additional information (histology, lab values)
70	F	Pruritus (2)	Triamcinolone acetonide cream	CR	Specimen submitted and diagnosis: 1. Skin histology analysis, right upper back scapular region, biopsy-punch 2. Perivascular lymphocytic dermatitis
62	F	Xerosis (1)	Ammonium lactate 12%	PR	
67	M	Acneiform rash (1) Xerosis (2) Nasal vestibulitis skin infection (1)	Metronidazole 1% cream Ammonium lactate 12% Mupirocin 2% ointment	SD PR SD	
55	F	Acneiform rash (1) Xerosis (1)	Alclometasone 0.05%/dapson 5% gel Ammonium lactate 12%	PR	
41	F	Xerosis (2)	Ammonium lactate 12% and salicylic acid 6%	PR	
59	F	Paronychia (2) Xerosis (1)	Nail avulsion	CR	Specimens submitted: 1. Left great toe; partial nail avulsion

Supplemental Tables for:
 Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer
 Mario Lacouture et al.

Age (y)	Sex	AE (grade)	Intervention	AE outcome	Additional information (histology, lab values)
			Ammonium lactate 12%		2. Right great toe; partial nail avulsion – 2 pieces Diagnosis: 1. Nail, left great toe; partial nail avulsion: onychomycosis 2. Nail, right great toe; partial nail avulsion: onychomycosis Note: PAS stains were positive in both specimens
75	F	Pruritus (2) Xerosis (1) Brittle nails (1)	Triamcinolone acetonide cream Ammonium lactate 12% Biotin 2.5 mg/d	CR	
53	F	Acneiform rash (1) Xerosis (2)	Brimonidine tartrate 0.33% gel, metronidazole 0.75% cream Ammonium lactate 12%	SD PR	
73	M	Urticaria (2) Acneiform rash (1)	Clobetasol 0.05%, hydroxyzine Alclometasone 0.05%	CR	

Supplemental Tables for:
Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer
Mario Lacouture et al.

Age (y)	Sex	AE (grade)	Intervention	AE outcome	Additional information (histology, lab values)		
64	F	Acneiform rash/skin infection (2)	Fluocinolone acetonide oil 0.01%, cefadroxil	PR	Coagulase-negative <i>Staphylococcus</i> resistant		
			Xerosis (2)	Salicylic acid 6%, triamcinolone acetate		PR	
				Pruritus (2)		Pregabalin	PR
73	F	Paronychia (2) Xerosis (2)	Partial nail avulsion	PR	<i>Staphylococcus aureus</i> , <i>Proteus mirabilis</i> , <i>Morganella morganii</i>		
			Ammonium lactate 12%	PR			
48	F	Xerosis (2)	Salicylic acid 6%, ammonium lactate 12%	PR			
74	F	Alopecia (1)	Biotin 2.5 mg/d	SD			
		Pruritus (1)					
		Xerosis (1)	Ammonium lactate 12%	CR			
55	F	Acneiform rash (1)	Alclometasone 0.05%/dapson 5% gel	SD			
		Hyperpigmentation (1)	Hydroquinone 4%/salicylic acid 6%	NA			

Supplemental Tables for:
 Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer
 Mario Lacouture et al.

Age	Sex	AE (grade)	Intervention	AE outcome	Additional information (histology, lab values)
(y)		Xerosis (1)	Ammonium lactate 12%	SD	

Abbreviations: dAEs, dermatologic adverse events; CR, complete response; F, female; M, male; MRSA, methicillin-resistant *Staphylococcus aureus*; MSKCC, Memorial Sloan Kettering Cancer Center; NA, not available; NSCLC, non-small cell lung cancer; OTC, over-the-counter; PAS, Periodic acid-Schiff; PR, partial response; SD, stable disease; y, year(s).

Supplemental Tables for:
 Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer
 Mario Lacouture et al.

Table S2. NSCLC patients treated with osimertinib referred for dAEs at NTUH

Age (y)	Sex	Osimertinib initiation	AE (grade)	Intervention	AE outcome	Additional information
41	F	1L – 80 mg/d for 1 y	Acneiform rash (1), pruritus (1), xerosis (1)	Desloratadine and buclizine for pruritus; fluticasone 0.05% cream for trunk eczema; desoximetasone 0.25% ointment for limb eczema; tetracycline 1% ointment for fissures	Improved	
68	M	2L – 80 mg/d for 10 mo	Acneiform rash (1), pruritus (1), xerosis (1) paronychia (1)	Levocetirizine for pruritus; fluticasone 0.05% cream for eczema; tetracycline 1% ointment for fissures and paronychia; urea 10% cream for generalized xerosis	Pruritus and acneiform rash improved; paronychia persisted	Combine selumetinib 75 mg q12h
69	M	>3L – 80 mg/d for	Acneiform rash (1),	Tetracycline 1% ointment for	Acneiform rash and xerosis improved 3 mo	

Supplemental Tables for:
 Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer
 Mario Lacouture et al.

Age (y)	Sex	Osimertinib initiation	AE (grade)	Intervention	AE outcome	Additional information
		2 mo	xerosis (1), paronychia (3[1])	paronychia; silver nitrate application once weekly	later; paronychia improved 9 mo later	
53	M	3L – 40 mg/d for 2 mo	Paronychia (3[1]); pruritus (1), xerosis (1)	Doxymycin EC 100 mg/cap for 2 wk, tetracycline 1% ointment for paronychia; silver nitrate application once weekly; hydrocortisone acetate 1% ointment and tetracycline 1% ointment for fissures; desoximetasone 0.25% ointment bid for leg and trunk eczema	Pruritus and acneiform rash improved; paronychia grade 1 persisted for 7 mo	
65	F	2L – 80 mg/d for 9 mo	None			
47	F	1L – 80 mg/d for 2 mo	Acneiform rash (1),	Fluticasone for acneiform rash and	Acneiform rash improved; paronychia	

Supplemental Tables for:
 Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer
 Mario Lacouture et al.

Age (y)	Sex	Osimertinib initiation	AE (grade)	Intervention	AE outcome	Additional information
			xerosis (1), Paronychia (3[2])	tetracycline 1% ointment for fissures and paronychia; silver nitrate application once weekly; hydrocortisone acetate 1% ointment for xerosis; fusidic acid cream for folliculitis	persisted for 32 mo	
35	M	3L – 80 mg/d for 3 mo	Paronychia (2)	Silver nitrate application every wk	Paronychia improved 1 mo later	Combine selumetinib 75 mg q12h
57	F	3L – 80 mg/d for 1 mo	Acneiform rash (1), xerosis (1), paronychia (3[1])	Levocetirizine and fluticasone for acneiform rash and tetracycline 1% ointment for fissures and paronychia; silver nitrate application once weekly; hydrocortisone acetate 1% ointment for acneiform rash; urea	Acneiform rash improved; xerosis and paronychia persisted for 4 mo	

Supplemental Tables for:
 Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer
 Mario Lacouture et al.

Age (y)	Sex	Osimertinib initiation	AE (grade)	Intervention	AE outcome	Additional information
				10% cream for generalized xerosis		
87	M	3L – 80 mg/d for 9 mo	Xerosis (1), pruritus (3)	Tetracycline 1% ointment for fissures; hydrocortisone acetate 1% ointment for xerotic eczema; fexofenadine 120 mg/d and doxepin 25 mg plus buclizine 50 mg every night for pruritus; aprepitant 125 mg loading and then 80 mg every other day for refractory pruritus	Xerosis and pruritus persisted for 9 mo	
47	F	2L – 80 mg/d for 7 mo	None			
52	F	2L – 80 mg/d for 15 mo	None			
72	F	2L – 80 mg/d	None			

Supplemental Tables for:
 Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer
 Mario Lacouture et al.

Age (y)	Sex	Osimertinib initiation	AE (grade)	Intervention	AE outcome	Additional information
		for 10 mo				
79	F	2L – 80 mg/d	None			
		for 6 mo				
66	F	2L – 80 mg/d	None			
		for 6 mo				
53	F	2L – 80 mg/d	Paronychia (1)	Tetracycline 1% ointment for paronychia; silver nitrate application once weekly	Paronychia improved 1 mo later	
		for 2 mo				
60	F	1L – 160 mg/d for 2 y and 4 mo	Pruritus (1), xerosis (1)	Hydrocortisone acetate 1% ointment for xerosis; chlorpheniramine maleate/lidocaine ointment for pruritus	Improved 1 mo later	
57	F	3L – 80 mg/d	None			
		for 2 mo				
52	F	>3L – 80 mg/d for 3 mo	Pruritus (1)	Levocetirizine for pruritus	Improved 1 mo later	

Supplemental Tables for:
 Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer
 Mario Lacouture et al.

Age (y)	Sex	Osimertinib initiation	AE (grade)	Intervention	AE outcome	Additional information
48	F	2L – 80 mg/d for 2 mo	None			
76	F	3L – 80 mg/d for 7 mo	Paronychia (1)	Tetracycline 1% ointment for paronychia	Paronychia improved 2 mo later	Combine selumetinib 50 mg q12h
48	F	>3L – 80 mg/d for 5 mo	Paronychia (1)	Tetracycline 1% ointment for paronychia	Paronychia improved 1 mo later	Combine selumetinib 75 mg q12h
79	F	2L – 80 mg/d for 2 mo	Acneiform rash (2), xerosis (1), pruritus (1)	Desoximetasone 0.25% ointment bid for limb eczema; chlorpheniramine maleate/lidocaine ointment for pruritus; urea 10% cream for xerosis; tetracycline 1% ointment for fissures and wounds; fusidic acid cream for folliculitis	Acneiform rash, pruritus, xerosis improved 6 mo later	
57	F	2L – 80 mg/d for 2 mo	Acneiform rash (2),	Tetracycline 1% ointment for	Acneiform rash improved, pruritus,	Combine selumetinib 75 mg q12h

Supplemental Tables for:
 Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer
 Mario Lacouture et al.

Age (y)	Sex	Osimertinib initiation	AE (grade)	Intervention	AE outcome	Additional information
			xerosis (2), pruritus (2), paronychia (3[2])	paronychia; sliver nitrate treatment monthly; hydrocortisone acetate 1% ointment for xerotic eczema; clobetasol propionate ointment for eczema on the legs; oral cephalexin for severe paronychia on the right big toe	xerosis, and paronychia persisted for 12 mo	
75	F	2L – 80 mg/d for 7 mo	None			
61	F	>3L – 80 mg/d for 22 mo	None			
59	F	2L – 80 mg/d for 2 mo	None			
81	F	3L – 80 mg/d for 1 mo	Acneiform rash (3); cellulitis	Oral cephalexin for right leg cellulitis; chloramphenicol	Acneiform rash improved after intravenous cephalexin	

Supplemental Tables for:
 Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer
 Mario Lacouture et al.

Age (y)	Sex	Osimertinib initiation	AE (grade)	Intervention	AE outcome	Additional information
				ointment for wounds and pustules	and D/C osimertinib	
57	M	2L – 80 mg/d for 2 mo	Xerosis (1), paronychia (1)	Tetracycline 1% ointment for paronychia; moisturizer for xerosis	Xerosis and paronychia persisted for 4 mo	Combine selumetinib 75 mg q12h
65	F	3L – 80 mg/d for 9 mo	None			
61	M	2L – 80 mg/d for 2 mo	None			
60	F	3L – 80 mg/d for 2 mo	Acneiform rash (1), xerosis (1), pruritus (1)	Desoximetasone 0.25% ointment for eczema on the four limbs; moisturizer use	Acneiform rash, xerosis and pruritus improved 1 mo later	
78	M	3L – 40 mg/d for 26 mo and then change to 80 mg/d for 14 mo	None			

Supplemental Tables for:
 Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer
 Mario Lacouture et al.

Age (y)	Sex	Osimertinib initiation	AE (grade)	Intervention	AE outcome	Additional information
76	F	2L – 80 mg/day for 5 mo	None			
77	F	3L – 80 mg/d for 1 mo	Paronychia (1), pruritus (2), acneiform rash (1), xerosis (1)	Chloramphenicol ointment for wounds; buclizine for pruritus; desoximetasone 0.25% ointment for acneiform rash; urea 10% cream for xerosis	Acneiform rash improved 2 mo later; pruritus, xerosis, and paronychia persisted for 4 mo	

1L, first line; 2L, second line; 3L, third line; bid, twice daily; D/C, discontinue; EC, enteric coated; F, female; M, male; mo, month(s); NSCLC, non-small cell lung cancer; NTUH, National Taiwan University Hospital; wk, week(s); y, year(s).